A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2022-09-05
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Nausea — outcome: UNKNOWN; onset 2023-01-04 (study day 101); relationship: not assessed
mild
assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-06-19 (study day 267); relationship: N
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-01 (study day 279); relationship: not assessed
Data queries
No data queries.